Found: 21
Select item for more details and to access through your institution.
A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 249, doi. 10.1093/jcag/gwab002.215
- By:
- Publication type:
- Article
Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 6, p. 821, doi. 10.1111/j.1365-2036.2007.03425.x
- By:
- Publication type:
- Article
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 6, p. 847, doi. 10.1111/j.1365-2036.2007.03427.x
- By:
- Publication type:
- Article
Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 8, p. 949, doi. 10.1111/j.1365-2036.2007.03286.x
- By:
- Publication type:
- Article
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 6, p. 733, doi. 10.1111/j.1365-2036.2007.03252.x
- By:
- Publication type:
- Article
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 2, p. 207, doi. 10.1111/j.1365-2036.2006.03182.x
- By:
- Publication type:
- Article
Blood oxidative stress markers are unreliable markers of hepatic steatosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2006, v. 23, n. 1, p. 91, doi. 10.1111/j.1365-2036.2006.02719.x
- By:
- Publication type:
- Article
Review article: an unexpected virus–host interaction – the hepatitis C virus-diabetes link.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2005, v. 22, p. 56, doi. 10.1111/j.1365-2036.2005.02598.x
- By:
- Publication type:
- Article
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
- Published in:
- 2010
- By:
- Publication type:
- journal article
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 9, p. 856, doi. 10.1111/apt.14261
- By:
- Publication type:
- Article
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2016, v. 44, n. 8, p. 877, doi. 10.1111/apt.13770
- By:
- Publication type:
- Article
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 10, p. 1209, doi. 10.1111/apt.12963
- By:
- Publication type:
- Article
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 9, p. 1081, doi. 10.1111/apt.12946
- By:
- Publication type:
- Article
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 37, n. 6, p. 655, doi. 10.1111/apt.12219
- By:
- Publication type:
- Article
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C ( ANRS HC16 GAMMATRI).
- Published in:
- Journal of Gastroenterology & Hepatology, 2013, v. 28, n. 2, p. 329, doi. 10.1111/jgh.12060
- By:
- Publication type:
- Article
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest–ActiTest) in patients infected by hepatitis B virus.
- Published in:
- Journal of Viral Hepatitis, 2009, v. 16, n. 3, p. 203, doi. 10.1111/j.1365-2893.2008.01065.x
- By:
- Publication type:
- Article
FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Fatigue in patients with chronic hepatitis C.
- Published in:
- Journal of Viral Hepatitis, 2002, v. 9, n. 4, p. 295, doi. 10.1046/j.1365-2893.2002.00364.x
- By:
- Publication type:
- Article
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.
- Published in:
- Journal of Viral Hepatitis, 2002, v. 9, n. 2, p. 128, doi. 10.1046/j.1365-2893.2002.00341.x
- By:
- Publication type:
- Article
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update.
- Published in:
- Journal of Viral Hepatitis, 2001, v. 8, n. 1, p. 48, doi. 10.1046/j.1365-2893.2001.00271.x
- By:
- Publication type:
- Article